Director Steven W. Lefkowitz filed a Form 4 with the SEC on November 20, 2026, disclosing a purchase of 11,500 shares of CorMedix Inc. common stock on November 18, 2026.

Key Highlights

  • Transaction: Steven W. Lefkowitz acquired 11,500 shares of CorMedix common stock on November 18, 2026, at a price of $4.53 per share.
  • Transaction code: The filing reports a "P" (open-market purchase) code for the transaction.
  • Direct holdings after transaction: Following the purchase, Lefkowitz directly held 137,451 shares of common stock.
  • Indirect holdings: Lefkowitz also beneficially owns 30,152 shares through Wade Capital Corporation Money Purchase Plan and 2,000 shares held by his wife.
  • Relationship to issuer: The reporting person is identified as a Director of CorMedix Inc. (NASDAQ:CRMD).

Lefkowitz's November 2026 Open-Market Purchase of CorMedix Common Stock

According to the Form 4 filed on November 20, 2026, Steven W. Lefkowitz, a director of CorMedix Inc. (NASDAQ:CRMD), purchased 11,500 shares of the company's common stock on November 18, 2026, at a price of $4.53 per share. The transaction was recorded under transaction code "P," indicating an open-market purchase. The filing was signed by Beth Zelnick Kaufman as attorney-in-fact.

Following the reported transaction, the filing discloses that Lefkowitz directly owned 137,451 shares of CorMedix common stock. In addition to his direct holdings, the filing reports two categories of indirect beneficial ownership: 30,152 shares held through Wade Capital Corporation Money Purchase Plan, described as "an entity for which the Reporting Person has voting and investment control," and 2,000 shares held by the reporting person's wife.

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not checked. No derivative securities activity was reported in Table II of the filing.

What Was Disclosed

The filing discloses a direct open-market purchase of 11,500 CorMedix shares at $4.53 by Director Steven W. Lefkowitz on November 18, 2026, bringing his direct beneficial ownership to 137,451 shares, with additional indirect holdings of 32,152 shares in total.